Revvity's post-divestiture reset appears to be gaining traction, with quarterly revenue rising from $664.8M in 2025Q1 to $728.9M in 2026Q3 and operating margin improving from 10.7% to 13.1% over the same stretch, suggesting operating leverage is returning.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue and gross margin have recovered from the depressed 43.8% reading in 2025Q4 to 57.4% in 2026Q3, though net margin of 8.5% still trails the 13-14% levels seen in 2024.
Revvity has a 40-year legacy in prenatal healthcare, pioneering Down syndrome screening and developing NIPT systems that transformed care.
Revvity issued revenue guidance expecting Q4 2025 sales of $772 million and full-year 2025 revenue of $2.86 billion, with mid-single-digit growth.
Revvity announced a collaboration with Eli Lilly to integrate Lilly's TuneLab AI models into the Revvity Signals platform, enhancing AI-driven analytics.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $1.38+6.2% vs $1.30 | $729M+4.9% vs $695M |
Q3 2026 Aug 4, 2026 | $1.41+16.5% vs $1.21 | $711M+1.1% vs $703M |
Q2 2026 May 5, 2026 | $1.06+3.9% vs $1.02 | $711M+1.0% vs $704M |
Q1 2026 Feb 2, 2026 | $1.70+8.3% vs $1.57 | $772M+0.9% vs $765M |
GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benchmark RVTY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Revvity, Inc. (RVTY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $155.11 | $17.3B | 68.51 | 3.67% | 8.61% | 3.5% | 0.19% | |
| $457.60 | $34.22B | 459.62 | 6.99% | 1.75% | 0.81% | — | |
| $61.31 | $9.33B | -75.77 | 2.08% | -3.51% | -5.05% | 0.24% | |
| $1722.15 | $34.8B | 36.91 | 3.98% | 22.25% | 14966.09% | — | |
| $381.57 | $10.27B | 10.05 | 0.65% | 39.45% | 14.07% | — | |
| $694.76 | $258.19B | 36.39 | 3.91% | 14.96% | 13.3% | 0.24% |
Revvity, Inc. (RVTY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Revvity, Inc. (RVTY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Aug 4, 2026·SEC
May 5, 2026·SEC
Get notified when RVTY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Revvity, Inc. (RVTY) stock FAQ — growth, dividends, profitability & financials explained
Revvity, Inc. (RVTY) reported $2.94B in revenue over the trailing twelve months. Revenue was $2.86B in fiscal year 2025. That is 100% more than the $1.43B of fiscal year 1996.
Revvity, Inc. (RVTY) grew revenue by 4.6% over the trailing twelve months, compared with the twelve months before.
Yes. Revvity, Inc. (RVTY) earned $253.2M in net income over the trailing twelve months (a 8.6% net margin).
Yes. Revvity, Inc. (RVTY) pays a dividend that yields 0.19% at the current price, a small yield.
Revvity, Inc. (RVTY) had a return on equity (ROE) of 3.5% over the trailing twelve months. That is below the market's typical 10-15%.
Revvity, Inc. (RVTY) generated $591.6M in free cash flow over the trailing twelve months.
